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Abstract
Researchers are becoming increasingly concerned that the conﬁdentiality of their novel
biomolecule sequences is being jeopardised, particularly when these sequences are either
submitted to sequence databases or uploaded as query terms onto internet-based
bioinformatic software suites. The researcher’s fears stem from the fact that the actual
uploading of their sequences acts as a novelty destroying prior disclosure or publication,
and that this may subsequently preclude valid patent protection for the sequences. This
article addresses the key issues involved in the analyses of biomolecules, highlighting
potential risks taken by many researchers in regard to patent protection and suggests
possible ways in which these risks may be mitigated. Copyright # 2002 John Wiley &
Sons, Ltd.
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The requirements of patentability in
Europe
In order to obtain a valid European patent for any
invention, the invention must be novel (Art.54
European Patent Convention; EPC), exhibit an
inventive step (Art.56 EPC), and be susceptible of
industrial application (Art.57 EPC). An invention is
regarded as being novel if it does not form part of
the state of the art. The state of the art consists of
everything made available to the public anywhere in
the world prior to the ﬁling date of a European
patent application. An invention is taken to involve
an inventive step if, when judged by a person skilled
in the art at the time of ﬁling the patent application,
it is not merely an obvious development of the state
of the art. Finally, an invention is considered as
being susceptible of industrial application if it can
be made or used in any kind of industry, including
agriculture.
In order to obtain a patent directed to a newly
discovered biomolecule, for example, a sequence or
partial sequence of a gene or protein, one facet of
novelty is that the biomolecule must be in an
isolated form (Art.5(2) European Biotechnology
Directive; BD). In addition, in order to meet the
industrial applicability requirement, a speciﬁc utility
for the sequence or partial sequence which is
beyond the realm of mere speculation must be
disclosed at the ﬁling date of the patent application
(Art.5(3) BD). Hence, it is determining which
speciﬁc parts of a genome constitute functional
genes, and what the functions of those genes are,
that may lead to patentable inventions.
At a time when the genome projects of numerous
organisms are nearing completion and, in many
cases, where the genomes have been fully
sequenced, a large amount of biomolecular data is
being constantly generated at an incredible rate.
Consequently, researchers are ﬁling patent applica-
tions for all types of biomolecules in an attempt to
protect their intellectual property stemming from
this mass of genomic data. In order for these inven-
tions to form the subject of valid patents, they must
meet all the requirements of patentability men-
tioned above. Therefore, when assessing whether a
biomolecule is patentable, one of the ﬁrst questions
that must be asked is: ‘Is it new?’ The question of
novelty is very strict and, as part of the requirement
for novelty, the biomolecule must be conﬁdential
when a patent application in respect of that bio-
molecule is ﬁled. If the sequence of the biomolecule
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ble to the public in any way whatsoever prior to the
ﬁling date of the patent application, then its novelty
may be in doubt. Hence, the validity of the pro-
spective patent may be at risk.
As part of the process of genome research,
speciﬁcally genome sequencing, the nucleic acid
sequences of newly discovered genes are normally
made publicly available as cDNAs, via online data-
bases such as those of the European Molecular
Biology Laboratory (EMBL), and GenBank. In
addition, newly discovered proteins are often pub-
lished via online databases such as Swiss-PROT and
the Martinsried Institute for Protein Sequences
(MIPS). GenBank, the EMBL Nucleotide Sequence
Database and the DNA Databank of Japan
(DDBJ) provide those submitting a sequence to
their database with the option of specifying that the
sequence data is not added to the online database,
and is held conﬁdential for a speciﬁed period of
time (a ‘holding period’). For example, the sub-
mitter may require that the sequence is added to the
online database only after the sequence has been
published in a journal, or after a patent application
has been ﬁled in respect of that sequence, thereby
maintaining its conﬁdentiality. Around 70–80% of
new sequences submitted to the EMBL nucleotide
database are subjected to such a conﬁdential hold-
ing period and neither the EBI nor the EPO regard
this as a novelty destroying public disclosure (Peter
Stoehr, personal communication).
Prior to ﬁling a patent application directed to a
biomolecule such as a nucleic acid or protein, it is
often advisable to investigate the novelty of the
sequence of that biomolecule to avoid ﬁling an
application for a biomolecule that has already been
publicly disclosed, possibly via one of these online
databases, or otherwise. The European Patent Orga-
nisation (EPO) provides various search facilities for
biomolecules by which these investigations may be
carried out (http://www.european-patent-ofﬁce.org/
dg1/ssp/html). The EPO website includes a clear
statement that sequence searching carried out by
the EPO is strictly conﬁdential and therefore does
not risk the novelty of the sequences searched in
terms of patentability.
The purpose of this paper is to investigate the
novelty of biomolecules forming the subject matter
of patents and patent applications. Speciﬁcally, it
analyses the use of online bioinformatics software
by researchers to determine putative structure and
function of their newly sequenced biomolecules, and
whether such use online amounts to a prior public
disclosure of that biomolecule. As noted above,
such a public disclosure may well invalidate a later
ﬁled patent application directed to that biomole-
cule.
Biology using The Internet
Online bioinformatics is carried out via a network
of computers as illustrated by Boxes A-D in
Figure 1. The sequence of a biomolecule which, for
the purposes of this paper, is a newly sequenced
nucleic acid denoted by the term SEQ ID, is stored
on a researcher’s computer, or client (Box A). For
example, SEQ ID may be a gene encoding a novel
polypeptide and is regarded as being conﬁdential
since it is within the conﬁnes of the researcher’s
computer. In addition, it is assumed that the
sequence has not been published in an academic
paper, publicly used or disclosed to third parties by
the researcher in any way. Hence, while the
sequence is still on the researcher’s computer, it is
still novel in terms of the patenting requirements. In
an attempt to determine whether SEQ ID is
expressed, the researcher’s next step might be to
upload the sequence as a query term for subsequent
bioinformatics analyses using the wide range of
structural and functional predictive software which
are currently freely available online via a software
server (Box C), for example, the National Centre
for Biotechnology Information (NCBI), the Human
Genome Mapping Project – Resource Centre
(HGMP-RC), or the European Bioinformatics
Institute (EBI) etc.
In the case of large pharmaceutical companies
and universities, the researcher’s computer is able to
contact the bioinformatics software server directly
via an in-house Internet gateway. However, in the
case of smaller organisations, or in circumstances
where the researcher accesses the software server
online from home, the researcher’s computer con-
tacts the software server via a commercial Internet
Service Provider (ISP) (Box B), for example,
Demon or AOL etc. In the latter case, the query
term is transferred to the ISP as a single packet of
data via a telephone line shown as path (i). The
query term is then divided up and sent as a number
of packets of data by the commercial ISP along
path (ii) to the software server where the packets
of data are reassembled to form the complete
query term, SEQ ID. The server, which provides
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Alignment Search Tool (BLAST) program, then
divides the query term up into a new set of data
packets and sends these along path (iii) to another
server (Box D). This second server, for example,
EMBL, provides an external database of sequences
against which the query term, SEQ ID, may be
searched.
Hence, by carrying out bioinformatics analysis of
SEQ ID online via the internet, the researcher has
voluntarily uploaded the conﬁdential query term
from his computer (Box A) onto a bioinformatics
software server (Box C), and, therefore, permitted
the software server to search the sequence against a
sequence database (Box D). The format of results
generated by bioinformatics analysis varies widely
depending on the predictive software and server
used, but in the case of the BLAST program, in
most cases the results consist of a detailed list of
homology scores and alignments with other seq-
uences in the database, which together may be used
to infer putative structure and function of the query
sequence, SEQ ID. Such data generated in silico is
often included in patent applications in an attempt
to meet the utility requirement mentioned above.
The results are delivered back to the researcher
from Box D to Box A along paths (iv), (v) and, in
some instances along path (vi), using any of three
possible methods available depending on the pre-
dictive software and server used. The three methods
for receiving the results of bioinformatics analysis
carried out online are as follows:-
Method 1
The search results may be viewed online at a unique
temporary Uniform Resource Locator (URL)
implemented by the software server. For example,
when using the interactive results option with the
BLAST program provided by the EBI server, the
researcher’s BLAST search is assigned a unique 18
digit directory path to where the results of the
search are automatically but temporarily posted,
and may be viewed online as a hypertext document
when the analysis has completed. The search results
are maintained online at this unique URL normally
for a period of about 24 hours; however, some large
ﬁles are deleted after about only 15 minutes.
Regardless of how long the URL is maintained
online, it is possible to view it, and the results, from
Figure 1. A schematic ﬂowchart illustrating a network of
computers during the use of bioinformatics software online.
A) The researcher’s computer on which the novel sequence
is saved. B) A local ISP, e.g. demon, AOL etc. C) A server
providing bioinformatics software online, e.g. NCBI, Wu-
BLAST. D) A server database against which the query term is
searched online, e.g. EMBL
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the web address window of a web browser.
Method 2
The search results are viewed online at a generic
temporary URL generated by the software server.
For example, when using the BLAST program
provided by the NCBI server, the researcher’s
sequence is automatically assigned an individual 18
digit request identiﬁer (ID) number shown in an ID
window, and then entered into a queue awaiting
analysis. Upon completion of the BLAST analysis,
the researcher must then press a ‘Format’ button to
view the results. Using the ID number, the server
then automatically posts the results of the search to
a temporary generic URL, linked to NCBI, which
may be viewed online by the researcher. The server
also provides the option of viewing the results of
different BLAST searches carried out earlier using
the NCBI server online by entering a different valid
request ID number into the ID window and viewing
these results at the same generic URL. A valid ID
number is one which has been assigned to a recent
BLAST search using NCBI, and consists of data
which is still stored in a temporary buffer and
which is therefore still available online. As with
Method 1, it is possible to view the URL and the
results from any PC online, providing a valid ID
number is inserted into the ID window.
Method 3
Some servers provide the researcher with the option
of having the results delivered directly back to them
via e-mail. For example, when using the BLAST
program provided by the IGH Montpellier server,
the researcher is given the option of entering his or
her private e-mail address into the relevant ﬁeld
prior to carrying out their bioinformatics analysis.
Once their e-mail address has been noted, analysis is
carried out with the subsequent results being sent to
the researcher shortly thereafter.
Discussion
When assessing whether a biomolecule which has
been subjected to online bioinformatics analysis
meets the novelty requirement for valid patent
protection, one needs to determine whether, in
doing so, that biomolecule has been ‘made available
to the public’ in terms of Art.54 EPC. Information
is said to be made ‘available’ to the public if only a
single member of the public is in a position to gain
access to it and understand it, and if there is no
obligation to maintain secrecy. If a person who was
able to gain knowledge of an invention was under
an obligation to maintain secrecy, the invention
cannot be said to have been made available to the
public, provided that person does not breach that
obligation. In addition, for a disclosure to be
novelty destroying, it must be an ‘enabling dis-
closure’. This means it must disclose information in
sufﬁcient detail such that the invention may be put
into practice by a skilled technician. For example,
in the case of a patent for a biomolecule, to be
novelty-destroying, the disclosure would have to
give details of the biomolecule’s sequence and
suggest at least one plausible function.
Finally, how an invention is actually made
available to the public is in fact immaterial. The
EPO Board of Appeal has held that the theoretical
possibility of having access to an invention renders
it in the public domain and, therefore, publicly
available, whatever the means by which the inven-
tion was made accessible. For example, the EPO
Board of Appeal has taken the view that if a
document in a library ‘would have been available to
anyone who requested to see it’ on any particular
day, then this was sufﬁcient to establish that the
document had been made available to the public on
that day. It is not necessary, as a matter of law, that
any member of the public would actually have been
aware that the document was available on that day,
or that any member of the public had actually taken
note of it. Therefore, it is not that someone would
view an unreferenced document in a library, the fact
that they could have viewed it, perhaps even by
chance by walking down a random aisle and view-
ing a random book on a randomly chosen shelf,
may be sufﬁcient to result in a novelty destroying
prior disclosure. Awareness, or actual inspection, of
the document and, hence, invention, does not need
to be proven in order for the disclosure to be
novelty-destroying. With this, and online bioinfor-
matics analysis, in mind, one needs to ascertain
whether any of the three available methods for
viewing the results of such analysis (Methods 1, 2 or
3), would result in those results having been ‘made
available to the public’.
In 2001, the World Intellectual Property Organi-
sation (WIPO) Standing Committee on Patent Law
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nal practices in Internet-related issues, in particular
with regard to publications on the Internet and the
security of material contained within e-mails. The
relevant document, available at (http://www.wipo.
int/scp/en/documents/session_5), is SCP/5/4. The gen-
eral consensus was that any website which may be
freely viewed and inspected online by third parties
over the internet is regarded as a publication, and
that any information contained in a web site prior
to the ﬁling date of a patent application acts as fully
citable prior art. From the survey results, it appears
that the relationship between the general availabil-
ity/accessibility of a website and it’s effect as prior
art highlighted a number of conﬂicting views
between the countries who took part. Whilst most
countries thought that the possibility of ﬁnding a
website disclosing an invention using a search
engine should be taken into account, some coun-
tries believed the degree of difﬁculty to access the
content of any disclosure, be it online or otherwise,
should not be relevant. Concerning the duration of
the website online, the consensus was that the
information should appear on the Internet long
enough such that it could be deemed to have been
made ‘available to the public’, this being judged on
a case by case basis. On this issue, more than one
country stated that, once the information was
posted on a website, it was a novelty-destroying
disclosure irrespective of the length of its appear-
ance on the Internet.
Hence, it appears that a publicly accessible
website is analogous to a book or journal which
may be found and read in a library, perhaps only
for a limited period of time, but long enough for
someone to physically ﬁnd it in the ﬁrst place.
Therefore, if an invention is described on a live and
freely available URL prior to the ﬁling date of a
patent application directed to that invention, and
with an enabling disclosure, then that website may
well be regarded as being a novelty-destroying
disclosure thereby invalidating that patent applica-
tion. To continue the analogy, posting the results of
a BLAST search to a URL as in either Method 1 or
2 may be described as being the equivalent of
placing a book disclosing the BLAST results in a
library without referencing it ﬁrst, which would still
render it publicly available in terms Art.54 EPC.
Theoretically, anybody could ﬁnd the URL and
gain access to the search results and the invention.
Using Method 1, anyone could compose a web
address for a server hosting bioinformatics software
(e.g. http://www.ebi.ac.uk/), and a directory path
(e.g. servicestmp), which may link to a page of
bioinformatics results. Each of these parts of the
web address are easily obtainable by simply explor-
ing the software server’s website and determining
approximately where results are posted. One could
then randomly enter digits constituting the ﬁle
name (e.g. 1234.html) until a valid URL showing a
recent set of search results was found. It is
appreciated that this may be a very time-consuming
process since the odds of ﬁnding a valid URL could
be as low as 1 in 10
17. Moreover, because the URL
showing the results is only available online for a
limited period of time, perhaps only a few hours or
so, then the time during which a URL address is
actually valid is relatively short. In view of the
survey results mentioned above, the accessibility of
the website, or the virtually ‘inaccessibility’ thereof,
may be a major factor in deciding whether it can be
said to have been made available to the public or
not. Unfortunately, the absence of legal precedents
in this area makes it impossible to conclude whether
a website, which is only online for a few hours and
incredibly difﬁcult to ﬁnd, would amount to a prior
disclosure. Nevertheless, theoretically, a valid URL
could be found, perhaps by using a powerful
number-generating algorithm, and it is this theore-
tical possibility which may well amount to publica-
tion of the URL in the eyes of the Courts. This
would be analogous to ﬁndings the Courts have
made in paper-based situations. Therefore, a patent
application directed to data disclosed on an online
website as in Method 1 could be found to be invalid
for lack of novelty.
Using Method 2, anyone is able to freely visit the
generic website hosted by the web server which has
the ID window and in which a search ID number
may be inserted. One could then insert ID numbers
until a valid one was found and thereby gain access
to the URL showing a recent set of search results.
As with Method 1, the likelihood of ﬁnding a valid
ID number linked to a URL is incredibly slim.
However, theoretically, it is possible and, similarly,
such a method of viewing search results could be
seen to be a publication and therefore novelty des-
troying. However, in contrast to using Method 1,
when using Method 2, an additional step has to be
taken in order to view a URL showing bioinfor-
matics results. Whereas in Method 1, one only has
to insert the digits directly into the web browser
URL window in the hope that a valid website is
found immediately, in Method 2, one must insert
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‘Format’ button before being linked to a URL.
Therefore, using Method 2, it is unlikely that any
third party attempting to access the results website
will have acted in good faith, since they could not
accidentally stumble upon it by a ‘simple’ typogra-
phical error.
Finally, using Method 3, the researcher’s results
are sent from Box C to Box A in Figure 1 via
e-mail. The survey conducted by the WIPO Stand-
ing Committee on Patent Law also questioned the
security of material contained within e-mails and, of
the 27 countries that responded on this issue, none
stated that they regarded a private e-mail as
constituting a public disclosure. This is irrespective
of whether encryption is used, and regardless of any
warning of conﬁdentiality which may be attached,
although it does assume that the recipient is bound
by a duty of conﬁdence. The general view is that an
e-mail is analogous to a letter or post-card which is
consigned to a postal delivery service. A postal
employee who sees the letter is not considered to be
a member of the public, and should not use the
information contained within the letter. Similarly,
an employee of an ISP is not considered to be a
member of the public and is therefore not free to
disclose the information they see in an e-mail, even
if there is no bar on employees of ISPs looking at
the content of an e-mail as it passes through their
servers.
The EBI do not regard the submission of a
biomolecule sequence as a query term to their
bioinformatics software as having been made pub-
licly available (Peter Stoehr, personal communica-
tion). The query sequence and the results are
temporarily stored by EBI, but are both deleted
shortly after the search has been completed. The
sequence and search results are not inspected at all
by the database and software support staff except
for the purpose of executing the user search and
providing user support, if necessary. Every effort is
made to keep such temporary data storage con-
ﬁdential and as secure as possible so that neither the
query sequence nor the results of the search are
made available to the public in any way. Therefore,
it would appear that neither the uploading of a
query term onto the EBI software server nor the
relaying of the results back to the researcher by
e-mail are novelty destroying acts per se. For a third
party to gain access to a temporarily stored query
term, or the results of a search, it would have to be
by some form of deliberate subterfuge. Intercepting
conﬁdential information along any of the paths (i)
to (vi) in Figure 1 may be possible using today’s
hacking methodologies. However, it is more likely
to occur when the information is temporarily stored
at either of boxes B, C or D where the sequence of
the biomolecule consists of a single packet of data
instead of a number of separate packets of data as
in paths (ii) to (v) which may be difﬁcult to
correctly reassemble in to SEQ ID.
Non-prejudicial disclosures
Unfortunately, things can and do go wrong. A
postal worker, sequence database employee or ISP
employee may read a letter or e-mail describing an
invention and publicly disclose what they have seen.
Alternatively, a computer hacker may intercept
conﬁdential information describing an invention
along paths (i) to (vi) shown in Figure 1 using a
‘packet sniffer’, and disclose that information to
third parties. It is evident that, in all cases, the
novelty of the invention and patent application will
be put at risk through no direct fault of the
patentee. Fortunately, if any of these circumstances
do arise, it is possible that such actions would
be viewed by the Courts as a breach of conﬁdence
by the employees or being unlawfully obtained
by a hacker, and therefore be regarded as non-
prejudicial disclosures. European patent law accounts
for two scenarios in which a prior disclosure of an
invention does not prejudice the novelty of a
subsequent patent application for that invention,
providing the prior disclosure occurred no earlier
than six months preceding the ﬁling date of a
European patent application (Art.55 EPC). The
ﬁrst scenario is if the patentee had displayed the
invention at an ofﬁcial international exhibition or
conference. The second scenario is if the disclosure
was due to an evident abuse in relation to the
patentee, which would include the breach of
conﬁdence or unlawful obtaining of information
described above. Providing either of these two
scenarios occur, there is a six month period of
grace in which a valid patent application may still
be ﬁled.
In order to take advantage of Art.55 EPC, the
patentee needs to show that an evident ‘abuse’ had
occurred to their detriment. It has been suggested
that deliberate intention to harm another party may
constitute evident abuse, as would knowledge of the
possibility of the harm resulting from a planned
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determine whether the hacker or database/ISP
employee intends to harm the patentee by carrying
out an act of disclosure. It is possible that the same
consideration may be applied to the case where an
individual intentionally attempts to access a unique
URL showing results from Method 1 or Method 2.
In this case, someone could locate a results page by
the random insertion of digits into the URL win-
dow (Method 1) or ID number (Method 2). Such an
act could be seen as on a par with attempting to
view a website which is only accessible by a secret
password, and therefore as an ‘abuse’ in accordance
with Art.55 EPC. Unfortunately, without the
beneﬁt of case law to help guide practitioners, it is
difﬁcult to say whether abuse has been committed,
and each of these scenarios would have to be judged
on a case-by-case basis.
Therefore, if Art.55 EPC is to come into play, it
is important to ensure that the employees or hacker,
who may see the query sequence, or read the e-mail/
letter by accident or intentionally, and who may
subsequently disclose the material contained in it,
clearly understands that he is acting unlawfully and/
or is bound by a duty of conﬁdence. Unfortunately,
the websites of EBI (and other database and soft-
ware providers) do not include a clear statement
indicating that they regard all information as being
conﬁdential. Therefore, a clear warning alerting the
reader to the conﬁdentiality of any material, be it
either a sequence uploaded onto a server, or bio-
informatics results being posted on to a webpage, or
being sent to the researcher via e-mail may increase
the chances of Art.55 EPC being applied.
Conclusion
Having examined the various methods by which the
results of online bioinformatics analysis may be
viewed or returned to the researcher, it is now
possible to categorise these alternatives according to
their risk of constituting a novelty destroying
publication under Art.54 EPC. Of the three meth-
ods discussed, it is the author’s view that having the
results returned via e-mail is likely to be the option
involving the least risk (Method 3). The general
consensus is that e-mails are conﬁdential commu-
nications between a sender and a recipient and are
not viewed as public disclosures. However, not all
servers provide the option of returning results by
e-mail. The method posing the next least risk is
when the software server assigns a unique user ID
search number which is used to view a URL at
which the results are temporarily posted (Method 2).
It is the author’s view that this method is less likely
to be seen as a publication because of the extra step
which must be taken by the researcher (or third
party) before activation of the results website
online. Using Method 1, where the results are
automatically posted onto a website, and where, in
theory, anyone could potentially see the website by
accident, probably poses the highest risk in respect
of acting as a publication, and it is suggested that
this method should be avoided if at all possible.
With all three methods, if a prior disclosure
occurs as a result of abuse by third parties who
have intercepted the online or e-mailed results, then
it may still be possible to ﬁle a patent application
with a valid claim to novelty, providing the
application is ﬁled within six months of that prior
disclosure, by taking advantage of Art.55 EPC. To
facilitate this, it is suggested that online software
servers and online databases include a clear secrecy
declaration stating that users’ query terms and
results are regarded as strictly conﬁdential, so that
any breach of this conﬁdence could be asserted to
be evident abuse.
It is interesting to speculate that if the Courts
adopt the view that results of bioinformatics
analyses carried out over the web which are posted
at an online website, albeit a temporary one, do act
as public disclosures (Methods 1 or 2), then we
could have a rather awkward situation in which a
patent directed to an online-researched biomolecule
may actually lack novelty and, therefore, be invalid.
If this were to be the case, one wonders how many
patents may be invalid because they cover bio-
molecules which used online bioinformatics prior to
ﬁling. Many large bioscience research organisations
adopt the policy of maintaining ‘local’ or ‘in-house’
sequence databases, and carry out all their bioinfor-
matics behind a secure ﬁrewall. The advantage of
this system is that there is no need to conduct
research online thereby avoiding any of the afore-
mentioned risks associated with working over the
Internet. Hence, it is the author’s view, that this
method is the most risk-free manner in which
bioinformatics research could be conducted, and
therefore cannot be recommended strongly enough
where cost is not a major issue. Disadvantages of
this system include the necessity for incredibly large
hard-drives on which the sequence databases and
bioinformatics software must be downloaded and
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continually update the sequence databases, nor-
mally on a daily basis, in order to avoid them
becoming out of date.
Most smaller organisations, such as biotech start-
up companies and many universities, do not have
the considerable ﬁnancial reserves required to set up
an in-house computing facility and manage query
tool support locally. As a result, it is entirely
possible that these organisations have conducted,
and are currently conducting, research over the
web, thereby disclosing their biomolecules before
the ﬁling date of a patent application.
Finally, if online bioinformatics is viewed as
acting as a novelty destroying prior disclosure, it
may be possible to take advantage of a twelve
month period of grace which is available for ﬁling
patent applications in the United States. If an
invention has been disclosed anywhere in the
world, for example on a website, then a patent
application may still be ﬁled with a valid claim to
novelty in the US providing it is ﬁled no later than
twelve months after that disclosure. It should be
noted that this grace period may only be used when
ﬁling for protection in the US. When valid patent
protection is sought in countries other than the US,
it is almost always necessary to ensure that an
invention has not been disclosed prior to the ﬁling
date.
The above relates to the author’s views on the
potential risks inherent with using online bioinfor-
matics, and should not be taken as legal advice for
any particular circumstances. If speciﬁc advice is
required, it is recommended that a Chartered or
European patent attorney be contacted.
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